Outcome of exercise of warrants in CombiGene

Nov 13, 2019

CombiGene AB (publ) (“CombiGene” or “the Company”) today announces the outcome of the exercise period of warrants of series 2018/2019 that was issued in conjunction with the Company’s preferential rights issue of units in September 2018. The exercise period ended September 30, 2019 and a total of 7,060 warrants were exercised for subscription of 7,060 shares at the subscription price of SEK 2.00 per share. By the exercise of warrants, CombiGene is supplied with approximately TSEK 14 before issue costs.

The exercise will increase the number of shares and votes in CombiGene by 7,060 shares from 63,723,836 to 63,730,896 shares and the share capital will increase with SEK 706.00 from SEK 6,372,383.60 to SEK 6,373,089.60, prior to registration of the directed issue to Lipigon Pharmaceuticals which the Company previously has published information about.

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.


Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden

Linked In     Twitter      Facebook